![sam the ultimate mechanism designer cra sam the ultimate mechanism designer cra](https://i5.walmartimages.com/asr/b814a82c-3757-4e68-b445-744ee864d9bb.9a54acb785da5874b6282bd46f7c1b6a.jpeg)
She sits on the board of the Society of Clinical trials, the Scientific Leadership Council of the Digital Medicine Society, participates on the Good Clinical Trial Collaborative, and is a member of the National Academies of Science and Medicine: Forum on drug discovery, development and translation. Tenaerts brings more than 30 years of experience in clinical trials, as a researcher and academic, in medical device research operations, a hospital-based site administrator, and physician, most recently serving as executive director of the Clinical Trials Transformation Initiative (CTTI) at Duke University. Tenaerts will direct research at Medable to help identify, implement and make ubiquitous responsible decentralized trial strategies. Pam Tenaerts is on a mission to improve evidence generation in medicine, She believes we need new models to facilitate and scale the evidence generation system for health by creating re-usable, responsible and more effective ways to understand and treat disease.ĭr. In 2002 he co-founded Clinical Pathways (CP), LLC with Sandra “Sam” Sather.ĭr. And in compliance and data management auditing.Regulatory inspection preparation and post audit Root Cause Analysis, Gap Analysis and CAPA development.
![sam the ultimate mechanism designer cra sam the ultimate mechanism designer cra](https://docplayer.net/docs-images/53/32497360/images/74-0.png)
The remote and on-site monitoring of pediatric and adult pharmaceutical, biologic and medical device clinical trials.He is a frequent speaker at industry conferences, has authored multiple courses for clinical research training programs in various functional areas and has been an Item Writer on ACRP’s Exam Committee. He has over 30 years of clinical experience with a Bachelor of Science Degree in Nursing and has been certified by the Association for Clinical Research Professionals (ACRP) as a CCRA for approximately 15 years. He was also a clinical research coordinator at a clinical research site.Ĭharles “Chuck” Sather’s current focus of consulting is to promote efficiency in remote and on-site Monitoring and Auditing in a balanced, fair and amiable manner. John spent his early career as a regional CRA for SmithKline Beecham and a Clinical Trial Manager at Pfizer where he performed all site management activities as well as managed the pivotal Inhaled Insulin Trials. He was accountable for operational oversight of all clinical development programs. John was tasked to create and implement the infrastructure of the Clinical Operations Department globally. He was brought onboard by the founding scientists as one of the company’s first six employees. as Senior Director of Clinical Operations. John spent over 8 years at GlobeImmune, Inc. While at Fate, John rebuilt the Clinical Operations and Data Management Departments while being accountable for strategy, planning, and execution of all clinical programs in all phases of development.
![sam the ultimate mechanism designer cra sam the ultimate mechanism designer cra](https://docplayer.net/docs-images/53/32497360/images/41-0.png)
Before, JnC Clinical, John was the Vice President of Clinical Operations for Fate Therapeutics, Inc. Prior to joining Halloran, John led his own consulting firm, JnC Clinical, where he was engaged with organization types including a global CRO, a medical device startup, and a generic company as their Vice President of Clinical Operations or expert Clinical Advisor. John is an expert clinical operations leader who excels at operational strategic planning, oversight, and delivery of clinical development programs. During this time, he has been successful in all sizes and types of organizations as well as a myriad of therapeutic areas most recently oncology, hematology, immune-oncology, and rare disease. John Ferraro has more than 28 years of experience in Clinical Operations/Development within the biotechnology and pharmaceutical industry.